Skip to content

Haemonetics HAE Blood Center — Goodwill

Other segment segments

Hospital
$600.44M+9.5%
Plasma
$29.04M0.0%

Similar metrics at other companies

Atlantic Union Bankshares logo
AUBConsumer Banking — Goodwill
$473.15M+333%
Gentex logo
GNTXOther — Goodwill
$34.74M
National Healthcare logo
NHCInpatient Services — Goodwill
$5.92M0.0%
Community Financial System logo
CBUBanking And Corporate Services — Goodwill
$764.71M+4.4%
Knife River logo
KNFWest — Goodwill
$137.88M+11.5%
RadNet logo
RDNTImaging Center — Goodwill
$758.65M+19.9%

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's blood center — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's blood center — goodwill?
Haemonetics (HAE) reported blood center — goodwill of $26.89M in Q1 2026.
How has Haemonetics's blood center — goodwill changed year-over-year?
Haemonetics's blood center — goodwill decreased by 0.3% year-over-year, from $26.97M to $26.89M.
What does blood center — goodwill mean?
Reflects the intangible asset value representing the premium paid for acquisitions within the Blood Center segment that exceeds the fair value of net identifiable assets. This metric is critical for assessing the long-term value of past strategic investments and potential impairment risks.